A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials
Asit Parikh, David B. Clifford(Washington University in St. Louis), Irving H. Fox(Takeda (United States)), Michael H. Lev(Massachusetts General Hospital), Kristin Stephens(Millennium Engineering and Integration (United States)), Jesse Shick(Takeda (United States)), Mark Patti(Takeda (United States)), Serap Sankoh(Millennium Engineering and Integration (United States)), Megan McAuliffe(Takeda (Japan)), Eugene O. Major, James M. Provenzale(Duke Medical Center), Joseph R. Berger(University of Pennsylvania), Catherine Milch(Millennium Engineering and Integration (United States))
Cited by 6
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Recommendations on Angiographic Revascularization Grading Standards for Acute Ischemic Stroke
|Stroke|2013|1.7k
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
|New England Journal of Medicine|2006|792